FDA Approves Expanded Indication for Dexcom G5 Continuous Glucose Monitor

Date: 
January, 2017
December 20, 2016. The US Food and Drug Administration has approved an expanded indication for Dexcom's G5 Mobile Continuous Glucose Monitoring System. The G5 Mobile continuous glucose monitoring device can now be used alone, without supplementary fingerstick glucose testing, to measure blood glucose levels and make diabetes treatment decisions. This is the first US-approved continuous glucose monitoring system to receive this indication. Click here for full article